Xiajun Hu Yumiao Wei Xinxin Shuai
10.3389/fimmu.2021.799077
Front Immunol
2021 Dec 15;12:799077.
case report glucocorticoid therapy immune checkpoint inhibitor myocarditis myositis tislelizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34975911/
Antibodies, Monoclonal, Humanized / adverse effects Glucocorticoids / administration & dosage Immune Checkpoint Inhibitors / adverse effects Methylprednisolone / administration & dosage Myocarditis / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Ureteral Neoplasms / drug therapy
Antibodies, Monoclonal, Humanized / adverse effects Glucocorticoids / administration & dosage Immune Checkpoint Inhibitors / adverse effects Methylprednisolone / administration & dosage Myocarditis / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Ureteral Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Acute Kidney Injury / chemically induced Acute Kidney Injury / diagnosis Acute Kidney Injury / drug therapy Aged Chemical and Drug Induced Liver Injury / diagnosis Chemical and Drug Induced Liver Injury / drug therapy Chemical and Drug Induced Liver Injury / etiology Drug Administration Schedule Glucocorticoids / adverse effects Humans Male Methylprednisolone / adverse effects Myocarditis / chemically induced Myocarditis / diagnosis Myositis / chemically induced Myositis / diagnosis Myositis / drug therapy Programmed Cell Death 1 Receptor / immunology Severity of Illness Index Time Factors Treatment Outcome Ureteral Neoplasms / immunology Ureteral Neoplasms / pathology Antibodies, Monoclonal, Humanized Glucocorticoids Immune Checkpoint Inhibitors PDCD1 protein, human Programmed Cell Death 1 Receptor tislelizumab Methylprednisolone
PMC8714936
34975911
Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries
2021